ALBPS
Biophytis is a biotechnology company focused on developing transformative therapies that impact longevity and age-related conditions. It operates with a longevity research platform and has programs such as BIO101 targeting sarcopenia and obesity, aiming to improve mobility and healthspan. The company has a multinational footprint with offices in France, the United States, and Brazil, and engages in clinical development and investor communications as part of its strategic activities.
No recent news for this company.